Lexaria CEO letter details FDA pre-IND success, new Japan client, no 2022 equity raise

Lexaria Bioscience Corp.

FDA pre-IND meeting cleared path toward formal IND filing for DehydraTECH-CBD hypertension program; Phase 1(b) study expected in 2023.
Signed first Asian client Premier Wellness Science with minimum quarterly payments totaling $4.53M over five years.
Did not raise equity in 2022; management preserved capital; can survive most of 2023 without additional funding.
Human nicotine study dosing began in December; results expected early 2023.
Animal seizure study showed DehydraTECH-CBD competitive with Epidiolex; new R&D into dementia and diabetes underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.